Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biofrontera Newderm
Leverkusen, North Rhine-Westphalia, Germanybiofrontera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Biofrontera Newderm is a specialized biopharmaceutical company focused on dermatology, particularly the development and commercialization of photodynamic therapy (PDT) for non-melanoma skin cancer. Originally established as a subsidiary of Biofrontera AG, the company was fully acquired by the Japanese pharmaceutical firm Maruho in December 2023. Its core business revolves around Ameluz, a topical gel containing aminolevulinic acid, which is used alongside specialized LED lamps to treat actinic keratosis and other skin conditions. The company continues to support the clinical expansion and commercialization of these dermatological treatments globally.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small moleculeDevice
- Industry
- Pharma
02
Partnerships
Biofrontera AGMaruho
Beyond the preview
Go deeper on Biofrontera Newderm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biofrontera Newderm.